13 June 2025
EMADOC-1700519818-2194512
Committee for Veterinary Medicinal Products (CVMP)

Summary of opinion[1] (post-authorisation)

Daxocox

International non-proprietary name (INN): enflicoxib

On 12 June 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Daxocox. The marketing authorisation holder for this veterinary medicinal product is Ecuphar.

Daxocox is currently authorised as tablets for use in dogs for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease). The grouped variation concerns change(s) to therapeutic indication(s) - addition of a new therapeutic indication or modification of an approved one: treatment of pain and inflammation associated with orthopaedic or soft tissue surgery and alignment of the product information with version 9.1 of the QRD template.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union